These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 18641543

  • 1. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.
    Figurski MJ, Nawrocki A, Pescovitz MD, Bouw R, Shaw LM.
    Ther Drug Monit; 2008 Aug; 30(4):445-55. PubMed ID: 18641543
    [Abstract] [Full Text] [Related]

  • 2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C, Coquerel A, Ryckelynck JP, Hurault de Ligny B.
    Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
    [Abstract] [Full Text] [Related]

  • 4. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.
    Clin Pharmacokinet; 2009 Mar; 48(11):745-58. PubMed ID: 19817503
    [Abstract] [Full Text] [Related]

  • 5. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH.
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [Abstract] [Full Text] [Related]

  • 7. Comparison of 3 estimation methods of mycophenolic acid AUC based on a limited sampling strategy in renal transplant patients.
    Hulin A, Blanchet B, Audard V, Barau C, Furlan V, Durrbach A, Taïeb F, Lang P, Grimbert P, Tod M.
    Ther Drug Monit; 2009 Apr; 31(2):224-32. PubMed ID: 19214145
    [Abstract] [Full Text] [Related]

  • 8. A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients in the stable posttransplant period.
    Mathew BS, Fleming DH, Annapandian VM, Prasanna S, Prasanna CG, Chandy SJ, John GT.
    Ther Drug Monit; 2010 Apr; 32(2):136-40. PubMed ID: 20110849
    [Abstract] [Full Text] [Related]

  • 9. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T, Luszczynska P, Durlik M, Majchrzak J, Baczkowska T, Chrzanowska M, Sobiak J, Glyda M, Kuriata-Kordek M, Kamińska D, Krajewska M, Klinger M.
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [Abstract] [Full Text] [Related]

  • 10. A possible simplification for the estimation of area under the curve (AUC₀₋₁₂) of enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
    Fleming DH, Mathew BS, Prasanna S, Annapandian VM, John GT.
    Ther Drug Monit; 2011 Apr; 33(2):165-70. PubMed ID: 21383656
    [Abstract] [Full Text] [Related]

  • 11. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
    Patel CG, Harmon M, Gohh RY, Akhlaghi F.
    Ther Drug Monit; 2007 Feb; 29(1):87-95. PubMed ID: 17304155
    [Abstract] [Full Text] [Related]

  • 12. Limited sampling strategies for predicting area under the concentration-time curve of mycophenolic acid in islet transplant recipients.
    Al-Khatib M, Shapiro RJ, Partovi N, Ting LS, Levine M, Ensom MH.
    Ann Pharmacother; 2010 Jan; 44(1):19-27. PubMed ID: 19996322
    [Abstract] [Full Text] [Related]

  • 13. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
    Langers P, Cremers SC, den Hartigh J, Rijnbeek EM, Ringers J, Lamers CB, van Hoek B.
    Aliment Pharmacol Ther; 2005 Mar 01; 21(5):549-57. PubMed ID: 15740538
    [Abstract] [Full Text] [Related]

  • 14. A six-hour extrapolated sampling strategy for monitoring mycophenolic acid in renal transplant patients in the Indian subcontinent.
    Fleming DH, Mathew BS, John GT, Chandy SJ, Manivannan J, Jeyaseelan V.
    J Postgrad Med; 2006 Mar 01; 52(4):248-52. PubMed ID: 17102540
    [Abstract] [Full Text] [Related]

  • 15. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration.
    Langers P, Press RR, den Hartigh J, Cremers SC, Baranski AG, Lamers CB, Hommes DW, van Hoek B.
    Ther Drug Monit; 2008 Aug 01; 30(4):456-61. PubMed ID: 18641539
    [Abstract] [Full Text] [Related]

  • 16. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
    Sibbald C, Seto W, Taylor T, Saunders EF, Doyle J, Dupuis LL.
    Ther Drug Monit; 2008 Aug 01; 30(4):434-8. PubMed ID: 18641547
    [Abstract] [Full Text] [Related]

  • 17. Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen.
    Cattaneo D, Cortinovis M, Baldelli S, Gotti E, Remuzzi G, Perico N.
    J Clin Pharmacol; 2009 Jul 01; 49(7):773-81. PubMed ID: 19491334
    [Abstract] [Full Text] [Related]

  • 18. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C, Everolimus Phase 2 Study Group.
    Clin Pharmacol Ther; 2001 Jan 01; 69(1):48-56. PubMed ID: 11180038
    [Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics of mycophenolic acid in senile Chinese kidney transplant recipients.
    Wang CX, Meng FH, Chen LZ, Ren B, Li SX, Fei JG, Qiu J, Deng SX, Li J, Chen SY.
    Transplant Proc; 2007 Jun 01; 39(5):1392-5. PubMed ID: 17580146
    [Abstract] [Full Text] [Related]

  • 20. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y, Naito T, Matsushita T, Otsuka A, Ushiyama T, Ozono S, Hishida A, Kagawa Y, Kawakami J.
    Ther Drug Monit; 2008 Dec 01; 30(6):656-61. PubMed ID: 18978521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.